| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ferah Comert Onder, Kader Sahin, Murat Senturk, Serdar Durdagi, Mehmet A. Identifying highly effective coumarin-based novel cholinesterase inhibitors by in silico and in vitro studies. Journal of molecular graphics & modelling. vol 115. 2022-05-27. PMID:35623143. |
inhibition of high cholinesterase levels including acetylcholinesterase (ache) and butyrylcholinesterase (bche), is one of the most important strategies for the treatment of alzheimer's disease (ad). |
2022-05-27 |
2023-08-13 |
Not clear |
| Görsev Yener, Duygu Hünerli-Gündüz, Ebru Yıldırım, Tuba Aktürk, Canan Başar-Eroğlu, Laura Bonanni, Claudio Del Percio, Francesca Farina, Raffaele Ferri, Bahar Güntekin, Mihály Hajós, Agustín Ibáñez, Yang Jiang, Roberta Lizio, Susanna Lopez, Giuseppe Noce, Mario Parra, Fiona Randall, Fabrizio Stocchi, Claudio Babilon. Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. International journal of psychophysiology : official journal of the International Organization of Psychophysiology. 2022-05-19. PMID:35588964. |
here, an expert panel from the electrophysiology professional interest area of the alzheimer's association and global brain consortium reviewed the field literature on the effects of the most used symptomatic drug against add (i.e., acetylcholinesterase inhibitors) on erps and eros in add patients with mci and dementia at the group level. |
2022-05-19 |
2023-08-13 |
human |
| Doriano Lamba, Alessandro Pesares. Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer's Drug Galantamine. International journal of molecular sciences. vol 23. issue 9. 2022-05-14. PMID:35563466. |
as a case study, the inhibition of acetylcholinesterase by galantamine, a drug approved for the symptomatic treatment of alzheimer's disease, is reported. |
2022-05-14 |
2023-08-13 |
Not clear |
| Aidan Falvey, Santhoshi P Palandira, Eric H Chang, Fernanda M Consolim-Colombo, Kevin J Tracey, Valentin A Pavlo. The Cholinergic Drug Galantamine Ameliorates Acute Respiratory Distress Syndrome in Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 36 Suppl 1. 2022-05-13. PMID:35556727. |
cholinergic anti-inflammatory signalling can be activated by galantamine - a centrally acting acetylcholinesterase inhibitor that is also clinically approved (for the treatment of alzheimer's disease). |
2022-05-13 |
2023-08-13 |
mouse |
| Mohadeseh Kalari, Zeinab Abbasi, Marzieh Dehghan Shasaltaneh, Ali Khaleghian, Zahra Moosavi-Neja. A Cobalt-Containing Compound as a Stronger Inhibitor than Galantamine to Inhibit Acetylcholinesterase Activity: A New Drug Candidate for Alzheimer's Disease Treatment. Journal of Alzheimer's disease : JAD. 2022-05-09. PMID:35527546. |
a cobalt-containing compound as a stronger inhibitor than galantamine to inhibit acetylcholinesterase activity: a new drug candidate for alzheimer's disease treatment. |
2022-05-09 |
2023-08-13 |
Not clear |
| Ante Miličević, Goran Šink. Use of connectivity index and simple topological parameters for estimating the inhibition potency of acetylcholinesterase. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. vol 30. issue 4. 2022-05-09. PMID:35527825. |
acetylcholinesterase (ache) has proven to be an effective drug target in the treatment of neurodegenerative diseases such as alzheimer's, parkinson's and dementia. |
2022-05-09 |
2023-08-13 |
Not clear |
| Rzgar Tawfeeq Kareem, Fahimeh Abedinifar, Evan Abdolkareem Mahmood, Abdol Ghaffar Ebadi, Fatemeh Rajabi, Esmail Vessall. The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020. RSC advances. vol 11. issue 49. 2022-05-02. PMID:35498922. |
acetylcholinesterase inhibitors (achei) affect acetylcholine levels in the brain and are broadly used to treat alzheimer's. |
2022-05-02 |
2023-08-13 |
Not clear |
| b' Mehmet Koca, U\\xc4\\x9fur G\\xc3\\xbcller, P\\xc4\\xb1nar G\\xc3\\xbcller, Ziya Da\\xc4\\x9falan, Bilal Ni\\xc5\\x9fanc\\xc4\\xb. Design and Synthesis of Novel Dual Cholinesterase Inhibitors: In Vitro Inhibition Studies Supported with Molecular Docking. Chemistry & biodiversity. 2022-04-26. PMID:35470963.' |
the major cholinesterase enzymes, acetylcholinesterase (ache) and butyrylcholinesterase (bche), are important in the therapy of alzheimer's disease (ad) based on the cholinergic hypothesis. |
2022-04-26 |
2023-08-13 |
human |
| Nur Achsan Al-Hakim, Irda Fidrianny, Kusnandar Anggadiredja, Rachmat Mauludi. Effect of Banana (Musa sp.) Peels Extract in Nanoemulsion Dosage Forms for the Improvement of Memory: In vitro & In vivo Studies. Pharmaceutical nanotechnology. 2022-04-25. PMID:35466890. |
is a plant that is rich in phytochemical compounds, especially antioxidant, which is hypothesized to inhibit the activity of acetylcholinesterase, an enzyme associated with alzheimer's disease. |
2022-04-25 |
2023-08-13 |
Not clear |
| Songül Şahi. A single-molecule with multiple investigations: Synthesis, characterization, computational methods, inhibitory activity against Alzheimer's disease, toxicity, and ADME studies. Computers in biology and medicine. vol 146. 2022-04-24. PMID:35462270. |
the main objective of this study is to determine the drug-like properties of the title compound and to demonstrate its acetylcholinesterase inhibitory activity for the cholinergic hypothesis of alzheimer's disease. |
2022-04-24 |
2023-08-13 |
human |
| Ken-Ichiro Yamashita, Taira Uehara, Yoshihide Taniwaki, Shozo Tobimatsu, Jun-Ichi Kir. Long-Term Effect of Acetylcholinesterase Inhibitors on the Dorsal Attention Network of Alzheimer's Disease Patients: A Pilot Study Using Resting-State Functional Magnetic Resonance Imaging. Frontiers in aging neuroscience. vol 14. 2022-04-22. PMID:35450059. |
long-term effect of acetylcholinesterase inhibitors on the dorsal attention network of alzheimer's disease patients: a pilot study using resting-state functional magnetic resonance imaging. |
2022-04-22 |
2023-08-13 |
Not clear |
| Pavan Kumar Chintamaneni, Praveen Thaggikuppe Krishnamurthy, Sai Kiran S S Pindiprol. Polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease. RSC advances. vol 11. issue 10. 2022-04-15. PMID:35423107. |
acetylcholinesterase (ache) inhibitors such as donepezil, galantamine and rivastigmine are used for the management of dementia in alzheimer's disease (ad). |
2022-04-15 |
2023-08-13 |
Not clear |
| Cai-Hong Li, Wei-Feng Wang, Nsanzamahoro Stanislas, Jun-Li Yan. Facile preparation of fluorescent water-soluble non-conjugated polymer dots and fabricating an acetylcholinesterase biosensor. RSC advances. vol 12. issue 13. 2022-04-15. PMID:35424765. |
acetylcholinesterase (ache) has been demonstrated as a crucial enzyme in the development and treatment of alzheimer's disease (ad). |
2022-04-15 |
2023-08-13 |
Not clear |
| S Cunha, M Swedrowska, Y Bellahnid, Z Xu, J M Sousa Lobo, Ben Forbes, A C Silv. Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. International journal of pharmaceutics. 2022-04-12. PMID:35413397. |
acetylcholinesterase inhibitors are the most used drugs to manage alzheimer's disease, although they show low bioavailability in the brain. |
2022-04-12 |
2023-08-13 |
Not clear |
| Natalie Argueta, Emily Notari, Kinga Sziget. Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease. CNS drugs. 2022-03-30. PMID:35352296. |
currently, there are five us food and drug administration-approved drugs for the treatment of alzheimer's disease; three acetylcholinesterase inhibitors, memantine, and aducanumab. |
2022-03-30 |
2023-08-13 |
Not clear |
| Yulin Liu, Giuseppe Uras, Itse Onuwaje, Wenlong Li, Hong Yao, Shengtao Xu, Xinuo Li, Xinnan Li, James Phillips, Stephanie Allen, Qi Gong, Haiyan Zhang, Zheying Zhu, Jie Liu, Jinyi X. Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease. European journal of medicinal chemistry. vol 235. 2022-03-27. PMID:35339839. |
a series of sulfone analogs of donepezil were designed and synthesized as novel acetylcholinesterase (ache) inhibitors with the potent inhibiting aβ aggregation and providing neuroprotective effects as potential modalities for alzheimer's disease (ad). |
2022-03-27 |
2023-08-13 |
Not clear |
| Che-Sheng Chu, Chi-Fa Hung, Vinoth Kumar Ponnusamy, Kuan-Chieh Chen, Nai-Ching Che. Higher Serum DHA and Slower Cognitive Decline in Patients with Alzheimer's Disease: Two-Year Follow-Up. Nutrients. vol 14. issue 6. 2022-03-26. PMID:35334816. |
we investigated the association between omega-3 pufas and cognitive function in patients with alzheimer's disease (ad) receiving acetylcholinesterase inhibitors (acheis). |
2022-03-26 |
2023-08-13 |
Not clear |
| Dina A Refaay, Mohammed I Abdel-Hamid, Amal A Alyamani, Mamdouh Abdel Mougib, Dalia M Ahmed, Amr Negm, Amr M Mowafy, Amira A Ibrahim, Rania M Mahmou. Growth Optimization and Secondary Metabolites Evaluation of Plants (Basel, Switzerland). vol 11. issue 6. 2022-03-26. PMID:35336618. |
growth optimization and secondary metabolites evaluation of cyanobacteria comprise a good natural resource of a potential variety of neuro-chemicals, including acetylcholinesterase inhibitors essential for alzheimer's disease treatment. |
2022-03-26 |
2023-08-13 |
Not clear |
| Fredrik Ekström, Andrea Gottinger, Nina Forsgren, Marco Catto, Luca G Iacovino, Leonardo Pisani, Claudia Bind. Dual Reversible Coumarin Inhibitors Mutually Bound to Monoamine Oxidase B and Acetylcholinesterase Crystal Structures. ACS medicinal chemistry letters. vol 13. issue 3. 2022-03-18. PMID:35300078. |
the synergistic inhibition of monoamine oxidase b (mao b) and acetylcholinesterase (ache) is believed to provide a potentiated effect in the treatment of alzheimer's disease. |
2022-03-18 |
2023-08-13 |
Not clear |
| Xiaona Sun, Yujin Wang, Zhichao Lei, Shasha Yue, Li Chen, Jianbo Su. Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors. European journal of medicinal chemistry. vol 234. 2022-03-18. PMID:35303485. |
a series of novel 5-hydroxyl-1-azabenzanthrone derivatives were designed, synthesized and evaluated as dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease (ad). |
2022-03-18 |
2023-08-13 |
Not clear |